EP
CHRS icon

Essential Partners’s Coherus Oncology CHRS Stock Holding History

Essential Partners’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-803
Closed -$1.12K – 2889
2026
Q2 		$1.12K Sell
803
-740
-48% -$1.21K ﹤0.01% 2191
2026
Q1 		$2.61K Buy
1,543
+892
+137% +$1.58K ﹤0.01% 1894
2025
Q4 		$924 Buy
651
+87
+15% +$127 ﹤0.01% 2054
2025
Q3 		$925 Buy
564
+100
+22% +$111 ﹤0.01% 2040
2025
Q2 		$339 Buy
+464
New +$401 ﹤0.01% 1807

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
RE
Rydar Equities Weatherford, Texas $194M AUM 23.21% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners's CHRS Position: Q3 2026 in Review

Essential Partners sold out of Coherus Oncology (CHRS) in Q3 2026, closing a stake of 803 shares — an estimated $1.12K sold.

Essential Partners first reported a position in CHRS in Q2 2025 and held it in 5 quarters. The position peaked at $2.61K in Q1 2026. 7 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Essential Partners reported no remaining Coherus Oncology position as of Q3 2026 after selling out during the quarter.
  • Essential Partners sold 803 Coherus Oncology shares in Q3 2026, an estimated $1.12K.
  • Essential Partners first reported a position in Coherus Oncology in Q2 2025 and held it in 5 quarters.
  • Essential Partners's Coherus Oncology position peaked at $2.61K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.